399 related articles for article (PubMed ID: 25641570)
1. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
[TBL] [Abstract][Full Text] [Related]
2. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
3. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
[TBL] [Abstract][Full Text] [Related]
4. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
5. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
6. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
[TBL] [Abstract][Full Text] [Related]
7. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
[TBL] [Abstract][Full Text] [Related]
8. New era of liver transplantation for hepatitis B: a 17-year single-center experience.
Anselmo DM; Ghobrial RM; Jung LC; Weaver M; Cao C; Saab S; Kunder G; Chen PW; Farmer DG; Yersiz H; Baquerizo A; Geevarghese S; Han SH; Goldstein L; Holt CD; Gornbein JA; Busuttil RW
Ann Surg; 2002 May; 235(5):611-9; discussion 619-20. PubMed ID: 11981206
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
15. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.
Lu AW; Zheng SS; Wu MP; Shen Y; Yang RW
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):357-61. PubMed ID: 18693169
[TBL] [Abstract][Full Text] [Related]
19. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
